453 related articles for article (PubMed ID: 30826708)
1. A radiopharmaceutical [
Tang Y; Hu Y; Liu W; Chen L; Zhao Y; Ma H; Yang J; Yang Y; Liao J; Cai J; Chen Y; Liu N
Nucl Med Biol; 2019 Mar; 70():23-31. PubMed ID: 30826708
[TBL] [Abstract][Full Text] [Related]
2. Direct comparison of the in vitro and in vivo stability of DFO, DFO* and DFOcyclo* for
Raavé R; Sandker G; Adumeau P; Jacobsen CB; Mangin F; Meyer M; Moreau M; Bernhard C; Da Costa L; Dubois A; Goncalves V; Gustafsson M; Rijpkema M; Boerman O; Chambron JC; Heskamp S; Denat F
Eur J Nucl Med Mol Imaging; 2019 Aug; 46(9):1966-1977. PubMed ID: 31161258
[TBL] [Abstract][Full Text] [Related]
3. Zirconium-89 labeled panitumumab: a potential immuno-PET probe for HER1-expressing carcinomas.
Bhattacharyya S; Kurdziel K; Wei L; Riffle L; Kaur G; Hill GC; Jacobs PM; Tatum JL; Doroshow JH; Kalen JD
Nucl Med Biol; 2013 May; 40(4):451-7. PubMed ID: 23454247
[TBL] [Abstract][Full Text] [Related]
4. A comparison of DFO and DFO* conjugated to trastuzumab-DM1 for complexing
Cho H; Al-Saden N; Lam H; Möbus J; Reilly RM; Winnik MA
Nucl Med Biol; 2020; 84-85():11-19. PubMed ID: 31931305
[TBL] [Abstract][Full Text] [Related]
5.
Price EW; Carnazza KE; Carlin SD; Cho A; Edwards KJ; Sevak KK; Glaser JM; de Stanchina E; Janjigian YY; Lewis JS
J Nucl Med; 2017 Sep; 58(9):1386-1394. PubMed ID: 28280216
[TBL] [Abstract][Full Text] [Related]
6. 89Zr-DFO-J591 for immunoPET of prostate-specific membrane antigen expression in vivo.
Holland JP; Divilov V; Bander NH; Smith-Jones PM; Larson SM; Lewis JS
J Nucl Med; 2010 Aug; 51(8):1293-300. PubMed ID: 20660376
[TBL] [Abstract][Full Text] [Related]
7. Development of a novel long-lived immunoPET tracer for monitoring lymphoma therapy in a humanized transgenic mouse model.
Natarajan A; Habte F; Gambhir SS
Bioconjug Chem; 2012 Jun; 23(6):1221-9. PubMed ID: 22621257
[TBL] [Abstract][Full Text] [Related]
8. Light-Induced Radiosynthesis of
Klingler S; Fay R; Holland JP
J Nucl Med; 2020 Jul; 61(7):1072-1078. PubMed ID: 31924725
[TBL] [Abstract][Full Text] [Related]
9. Site-Specific Photoaffinity Bioconjugation for the Creation of
Delaney S; Nagy Á; Karlström AE; Zeglis BM
Mol Imaging Biol; 2023 Dec; 25(6):1104-1114. PubMed ID: 37052759
[TBL] [Abstract][Full Text] [Related]
10. Immuno-PET Imaging of CD30-Positive Lymphoma Using 89Zr-Desferrioxamine-Labeled CD30-Specific AC-10 Antibody.
Rylova SN; Del Pozzo L; Klingeberg C; Tönnesmann R; Illert AL; Meyer PT; Maecke HR; Holland JP
J Nucl Med; 2016 Jan; 57(1):96-102. PubMed ID: 26514172
[TBL] [Abstract][Full Text] [Related]
11. Measuring the pharmacodynamic effects of a novel Hsp90 inhibitor on HER2/neu expression in mice using Zr-DFO-trastuzumab.
Holland JP; Caldas-Lopes E; Divilov V; Longo VA; Taldone T; Zatorska D; Chiosis G; Lewis JS
PLoS One; 2010 Jan; 5(1):e8859. PubMed ID: 20111600
[TBL] [Abstract][Full Text] [Related]
12. Positron Emission Tomography Imaging of Platelet-Derived Growth Factor Receptor β in Colorectal Tumor Xenograft Using Zirconium-89 Labeled Dimeric Affibody Molecule.
Cai H; Shi Q; Tang Y; Chen L; Chen Y; Tao Z; Yang H; Xie F; Wu X; Liu N; Yang Y; Wu H; Tian R; Lu X; Li L
Mol Pharm; 2019 May; 16(5):1950-1957. PubMed ID: 30986347
[TBL] [Abstract][Full Text] [Related]
13. Lysine-Directed Site-Selective Bioconjugation for the Creation of Radioimmunoconjugates.
Sarrett SM; Rodriguez C; Rymarczyk G; Hosny MM; Keinänen O; Delaney S; Thau S; Krantz BA; Zeglis BM
Bioconjug Chem; 2022 Sep; 33(9):1750-1760. PubMed ID: 35946495
[TBL] [Abstract][Full Text] [Related]
14. Visualizing Galectin-3 Binding Protein Expression with ImmunoPET.
Keinänen O; Sarrett SM; Delaney S; Rodriguez C; Dayts EJ; Capone E; Sauniere F; Ippoliti R; Sala G; Iacobelli S; Zeglis BM
Mol Pharm; 2023 Jun; 20(6):3241-3248. PubMed ID: 37191353
[TBL] [Abstract][Full Text] [Related]
15. The Influence of Glycans-Specific Bioconjugation on the FcγRI Binding and
Vivier D; Fung K; Rodriguez C; Adumeau P; Ulaner GA; Lewis JS; Sharma SK; Zeglis BM
Theranostics; 2020; 10(4):1746-1757. PubMed ID: 32042334
[No Abstract] [Full Text] [Related]
16.
Chekol R; Solomon VR; Alizadeh E; Bernhard W; Fisher D; Hill W; Barreto K; DeCoteau JF; Parada AC; Geyer CR; Fonge H
Oncotarget; 2018 Mar; 9(24):17117-17132. PubMed ID: 29682209
[TBL] [Abstract][Full Text] [Related]
17. Cyclic versus Noncyclic Chelating Scaffold for
Summer D; Garousi J; Oroujeni M; Mitran B; Andersson KG; Vorobyeva A; Löfblom J; Orlova A; Tolmachev V; Decristoforo C
Mol Pharm; 2018 Jan; 15(1):175-185. PubMed ID: 29160082
[TBL] [Abstract][Full Text] [Related]
18.
Dias GM; Ramogida CF; Rousseau J; Zacchia NA; Hoehr C; Schaffer P; Lin KS; Bénard F
Nucl Med Biol; 2018 Mar; 58():1-7. PubMed ID: 29291493
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of Anti-LGR5 Antibodies by ImmunoPET for Imaging Colorectal Tumors and Development of Antibody-Drug Conjugates.
Azhdarinia A; Voss J; Ghosh SC; Simien JA; Hernandez Vargas S; Cui J; Yu WA; Liu Q; Carmon KS
Mol Pharm; 2018 Jun; 15(6):2448-2454. PubMed ID: 29718672
[TBL] [Abstract][Full Text] [Related]
20. Site-specifically labeled
Kristensen LK; Christensen C; Jensen MM; Agnew BJ; Schjöth-Frydendahl C; Kjaer A; Nielsen CH
Theranostics; 2019; 9(15):4409-4420. PubMed ID: 31285769
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]